Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis : workshop summary

The Resource Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis : workshop summary

Label

Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis : workshop summary

Title remainder

workshop summary

Statement of responsibility

Anna Nicholson, Rebecca A. English, Rita S. Guenther, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies

Language

eng

Summary

To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)--a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)--face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high-quality medicines to more of the people who need them

Cataloging source

NLM

Dewey number

362.19699/5

Funding information

This activity was supported by contracts between the National Academy of Sciences and Department of Health and Human Services (Contract Nos. N01-OD-4-2139 and HHSF223001003T), Abbott Pharmaceuticals, American Diabetes Association, American Society for Microbiology, Amgen Inc., Association of American Medical Colleges, Bristol-Myers Squibb, Burroughs Wellcome Fund, Celtic Therapeutics, LLLP, Critical Path Institute, Doris Duke Charitable Foundation, Eli Lilly and Company, Eli Lilly & Co. Foundation, FasterCures, Foundation for the NIH, Friends of Cancer Research, GlaxoSmithKline, Janssen Research & Development, LLC, March of Dimes Foundation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc.

Illustrations

illustrations

Index

no index present

LC call number

RC311.1

LC item number

.W67 2012

Literary form

non fiction

Nature of contents

dictionaries
bibliography
technical reports

NLM call number

WF 360

Structured data from the Bibframe namespace is licensed under the Creative Commons Attribution 4.0 International License by University of Missouri Libraries. Additional terms may apply to data associated with third party namespaces.

Context

Work of